FDA on CV Risk in Diabetics

The FDA Guidance released in 2008 offers industry insight to why evaluation of heart risk in clinical trials is necessary.

ICE E-14 Step 2

Guidance for Industry

Integrated Cardiovascular Safety

Early Accuracy in New Drug Safety Analysis

Cardiac Safety: The Merits of ECG Centralization